Etanercept: An evolving role in psoriasis and psoriatic arthritis Article

cited authors

  • Prodanovich, S; Ricotti, C; Glick, BP; Inverardi, L; Leonardi, CL; Kerdel, F

fiu authors

abstract

  • Tumor necrosis factor alpha (TNFα) plays a key pathophysiological role in psoriasis and psoriatic arthritis (PsA). Recent interest has thus focused on the clinical potential of TNFa antagonists (e.g. etanercept) in these settings. In psoriasis, several large pooled analyses and well-designed clinical trials documented the significant clinical efficacy and generally favorable tolerability of etanercept for up to 96 weeks. Similarly, in PsA, a large phase III trial showed that, etanercept significantly reduced arthritic symptoms and inhibited radiographic disease progression; sustained clinical benefit was again evident for up to 2 years. Etanercept is at the forefront of psoriatic disease management, and continued evolution and evaluation of the compound - for example, in detailed comparative studies and economic analyses - is likely to confirm a key role for etanercept in the treatment of psoriasis and PsA. © 2010 Adis Data Information BV. All rights reserved.

publication date

  • July 9, 2010

Digital Object Identifier (DOI)

start page

  • 3

end page

  • 9

volume

  • 11

issue

  • SUPPL. 1